Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
(NASDAQ: PPCB) Delayed: 0.61 -0.02 (3.17%)
Previous Close $0.63    52 Week High $ 
Open $0.66    52 Week Low $ 
Day High $0.67    P/E N/A 
Day Low $0.60    EPS $ 
Volume 160,446       

(NASDAQ: PPCB) Delayed: 0.61 -0.02 (3.17%)
Previous Close $0.63    52 Week High $ 
Open $0.66    52 Week Low $ 
Day High $0.67    P/E N/A 
Day Low $0.60    EPS $ 
Volume 160,446